Ab­b­Vie, Janssen, No­var­tis, Pfiz­er and UCB to joint­ly ad­vance 'dig­i­tal' end­point for atopic der­mati­tis

As the com­pe­ti­tion around the lu­cra­tive atopic der­mati­tis space heats up, Ab­b­Vie, Janssen, No­var­tis, Pfiz­er, and UCB are com­ing to­geth­er in a pre-com­pet­i­tive col­lab­o­ra­tion to ad­vance noc­tur­nal scratch as a “dig­i­tal” end­point for the skin con­di­tion.

The Big Phar­mas are hop­ing to dri­ve the broad­er ac­cep­tance of noc­tur­nal scratch as a mean­ing­ful end­point for atopic der­mati­tis, and for dig­i­tal end­points in gen­er­al.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN